The Bottom Line
Melanoma is staged using a system called TNM, which measures how deep the tumor is, whether it has reached your lymph nodes, and whether it has spread elsewhere in your body. Your stage—from 0 to IV—determines your prognosis and what treatment your doctor will recommend. Stage I melanoma carries a 97% five-year survival rate; early detection and staging are the most powerful tools for improving your outcome.
What Is Melanoma Staging?
When a dermatologist or surgeon removes a melanoma, the tissue is sent to a pathologist who examines it under a microscope and measures key features. These measurements are combined with information about your lymph nodes and any spread to other parts of the body to assign a “stage.” Your stage is a shorthand that tells your medical team how advanced the cancer is, what the prognosis is, and which treatments are most likely to help.
Melanoma is staged using a system called TNM, developed by the American Joint Committee on Cancer (AJCC). The current version (8th edition, 2017) is the most detailed and accurate system available.
The Three Parts of the TNM System
T — The Primary Tumor
The T stage describes the original tumor, primarily based on how thick it is (called Breslow thickness, measured in millimeters). Thickness is the single most important factor in predicting your prognosis. The pathologist also looks for ulceration (whether the surface of the tumor has broken down) and the rate of cell division (mitotic rate).
| T Stage | Thickness | Details |
|---|---|---|
| Tis | In situ only | Cancer is in the surface layer, has not invaded deeper skin |
| T1 | Less than 1 mm | T1a: no ulceration; T1b: ulceration or high mitotic rate |
| T2 | 1–2 mm | T2a: no ulceration; T2b: ulceration |
| T3 | 2–4 mm | T3a: no ulceration; T3b: ulceration |
| T4 | More than 4 mm | T4a: no ulceration; T4b: ulceration |
What does ulceration mean? If the top layer of the tumor has broken down, it is considered ulcerated. Ulceration is a sign of more aggressive biology and automatically moves you to the “b” subcategory at each thickness level, which slightly worsens the prognosis.
N — Lymph Nodes
The N stage tells your doctor whether cancer has spread to nearby lymph nodes. Lymph nodes are small glands that filter fluid and are part of your immune system. Melanoma often spreads to them first before reaching other organs.
- N0: No lymph node involvement
- N1: One lymph node affected
- N2: Two or three nodes, or cancer found between the tumor and lymph nodes (called in-transit metastases) without node involvement
- N3: Four or more nodes, or in-transit metastases combined with node involvement
To check your lymph nodes, your surgeon may recommend a sentinel lymph node biopsy (SLNB). In this procedure, a small amount of dye or radioactive tracer is injected near the tumor site. It travels to the first (sentinel) lymph node that drains the area. If the sentinel node is cancer-free, the other nodes are almost certainly cancer-free too. SLNB is recommended for tumors 1–4 mm thick. It finds hidden lymph node spread in 5–10% of these patients, which changes both the stage and the treatment plan.
M — Distant Metastases
The M stage indicates whether melanoma has spread to distant parts of the body:
- M0: No distant spread
- M1a: Spread to distant skin, soft tissue, or lymph nodes—best prognosis among Stage IV
- M1b: Spread to the lungs
- M1c: Spread to other internal organs (not the brain)
- M1d: Spread to the brain—the most serious category
Overall Stages and Survival Rates
The T, N, and M categories are combined into an overall stage from 0 to IV. Here are the stages with their approximate five-year survival rates (from the AJCC 8th edition data):
| Stage | Description | 5-Year Survival |
|---|---|---|
| 0 | In situ (surface only) | ~100% |
| IA | Thin (<0.8 mm), no ulceration, no spread | 97% |
| IB | Thin with ulceration or 1–2 mm, no spread | 92% |
| IIA | 1–2 mm with ulceration, or 2–4 mm, no spread | 81% |
| IIB | 2–4 mm with ulceration, or >4 mm, no spread | 70% |
| IIC | >4 mm with ulceration, no spread | 53% |
| III | Any thickness with lymph node involvement | 40–78% |
| IV | Spread to distant organs | 7–50% |
Note: Stage IV survival rates have improved significantly in recent years due to immunotherapy and targeted therapy. Figures above are based on population-level data and individual outcomes vary widely.
How Your Stage Guides Treatment
- Stage 0–IIA: Wide local excision (removing the tumor with a margin of healthy tissue) is usually the only treatment needed. The margin width depends on tumor thickness.
- Stage IIB–IIC: Wide local excision plus sentinel lymph node biopsy. Some patients at this stage may be offered clinical trials evaluating adjuvant immunotherapy.
- Stage III: Surgery plus adjuvant (post-surgery) immunotherapy (pembrolizumab or nivolumab) or targeted therapy (if BRAF-mutated). This significantly reduces the chance of recurrence.
- Stage IV: Systemic therapy is the primary treatment. This includes checkpoint inhibitor immunotherapy (nivolumab, pembrolizumab, or combination with ipilimumab), targeted therapy if BRAF-mutated (dabrafenib + trametinib), and radiation for specific sites such as brain metastases.
When to See a Dermatologist or Oncologist
- You have been diagnosed with melanoma and need staging information explained clearly
- Your doctor has recommended a sentinel lymph node biopsy and you want to understand the procedure and what results mean
- You have Stage III or IV melanoma and want to understand all available treatment options including clinical trials
- You have completed initial treatment and need guidance on follow-up monitoring
- You have a first-degree relative with melanoma and want to understand your own risk
Frequently Asked Questions
What does it mean if my pathology report says T3b N2a M0?
T3b means your tumor was 2–4 mm thick and had ulceration on the surface. N2a means 2–3 lymph nodes contained microscopic cancer deposits. M0 means no spread to distant organs. Together, this is Stage IIIB disease, with approximately 45–50% five-year survival. Your doctor will likely recommend surgery to fully remove the primary tumor and potentially affected lymph nodes, followed by adjuvant immunotherapy or targeted therapy.
Is sentinel lymph node biopsy required for all melanomas?
No. SLNB is recommended for melanomas 1–4 mm thick. For very thin melanomas (under 1 mm) without any high-risk features, the risk of lymph node involvement is low enough that SLNB may not be necessary. For very thick melanomas (over 4 mm), the risk of spread is high enough that staging imaging and broader evaluation take priority. Your surgeon will recommend what is appropriate based on your specific tumor characteristics.
Can my stage change after initial diagnosis?
Yes. Your initial stage is based on what is known from the biopsy. After surgery and sentinel lymph node biopsy, more precise staging information becomes available. Your stage may be revised upward if the SLNB shows lymph node involvement, or may be confirmed at the initial stage if nodes are clear. This is called pathological staging and is the most accurate assessment.
Does my stage determine whether I need immunotherapy?
Generally, yes. Stage I and most Stage II patients receive surgery alone. Starting at Stage III (lymph node involvement), adjuvant immunotherapy is often recommended to prevent recurrence. Stage IV disease almost always requires systemic immunotherapy or targeted therapy as the primary treatment.
References
- Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer 8th edition staging system. CA Cancer J Clin. 2017;67(6):472-492.
- Balch CM, Gershenwald JE, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19(16):3622-3632.
- Balch CM, Soong SJ, Atkins MB, et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin. 2004;54(3):131-149.
- Wong SL, Kattan MW, McMasters KM, et al. Sentinel lymph node biopsy for melanoma: prognostic value. Arch Surg. 2004;139(7):740-746.
- Swetter SM, Tsao H, Bichakjian CK, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019;80(1):208-250.
- Buzaid AC, Ross MI, Balch CM, et al. Critical analysis of the current AJCC staging system for cutaneous melanoma and proposal of a revised system. J Clin Oncol. 1997;15(3):1039-1051.
- Kalady MF, White RR, Johnson JL, et al. Thin melanomas: predictive lethal indices of metastasis. Ann Surg. 2003;238(4):528-537.
Trusted Resources
- American Academy of Dermatology: Melanoma Treatment
- Skin Cancer Foundation: Melanoma Stages
- National Cancer Institute: Melanoma Treatment
- Mayo Clinic: Melanoma Diagnosis and Treatment
Always consult a board-certified dermatologist or oncologist for personalized staging interpretation and treatment recommendations. This article is for educational purposes only.